CLBT — Cellebrite DI Ltd.

Summary of Cellebrite Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Annual Recurring Revenue (ARR): Increased 21% year-over-year to $493 million.
• Adjusted EBITDA: Reported at $30.6 million, up 29% year-over-year, with a margin of 23.9%.
• Free Cash Flow Margin: Maintained at 32% for the trailing 12 months.
• Revenue: Total revenue reached $128.3 million, a 19% increase from the previous year.
• Gross Profit: Increased 21% to $110.2 million, resulting in a gross margin of 86%.
• Net Income: Reported at $30.6 million, or $0.12 per fully diluted share.
• Employee Count: 1,271 employees as of March 31, 2026.

2. Strategic Updates and Business Highlights

• Product Innovation: Launched "Genesis," an AI-driven investigative analytics solution, receiving strong early feedback with over 500 registered users from various agencies.
• Guardian Investigate: An AI-powered case management system moved to general availability, enhancing digital evidence management capabilities.
• FedRAMP Certification: Achieved high-level FedRAMP authorization, allowing access to U.S. federal agencies for cloud-based solutions.
• Market Expansion: The U.S. federal business is rebounding, with a 35% year-over-year increase in the pipeline, driven by stabilization in agency leadership and targeted funding for digital initiatives.
• International Growth: EMEA ARR growth increased to 25%, particularly in the defense and intelligence sector.

3. Forward Guidance and Outlook

• Q2 ARR Guidance: Expected to be between $510 million and $513 million, indicating a sequential growth of approximately 50% at the midpoint.
• Revenue Guidance for Q2: Projected between $130 million and $133 million, representing a 15% to 17% increase.
• Adjusted EBITDA for Q2: Anticipated in the range of $29 million to $31 million.
• Long-term Outlook: The total addressable market (TAM) for investigative AI is estimated at $12.5 billion over the next four years, with a conservative revenue target of $600 million from AI products.

4. Bad News, Challenges, or Points of Concern

• Historical Headwinds: The company faced challenges in the previous year with flat growth in the U.S. federal segment, primarily due to budget pressures and organizational changes.
• Market Dynamics: The AI landscape is highly dynamic and unpredictable, posing risks in execution and competition.
• Potential Delays: Some deals were pushed from Q1, although the company remains optimistic about Q2 and beyond.

5. Notable Q&A Insights

• Customer Adoption: Management expressed confidence that the introduction of AI products like Genesis would not lead to customers delaying core investments; instead, they see it as enhancing overall value.
• Competitive Landscape: The emergence of AI tools like Anthropic Claude's Mythos was discussed, with management asserting that their proprietary technology and expertise differentiate them from generic AI solutions.
• Sales Strategy: The company is focusing on word-of-mouth marketing from early adopters to drive adoption, leveraging the strong community of existing users.
• Budget Environment: Management noted that geopolitical instability has created a tailwind for their business, with increased appropriations for digital evidence management and related solutions.

Overall, Cellebrite's first quarter of 2026 showcased strong financial performance, significant product innovations, and a positive outlook driven by strategic initiatives, despite some lingering challenges from the previous year.